KLVFF Peptide Dialysate for Beta-Amyloid Capture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reducing Beta-Amyloid levels, such as those in Alzheimer's disease, rely on semi-permeable membranes that are laborious to maintain and may not effectively target specific Beta-Amyloid peptides, often requiring intricate evaluation of membrane characteristics and risking escape of toxins back into the body.
Innovation Solution
A composition comprising a capturing and binding agent, specifically the KLVFF peptide or its variants, is introduced into the dialysate for extracorporeal treatment, binding to Beta-Amyloids and preventing their escape, using a standard dialysis machine to reduce Beta-Amyloid levels without relying on membrane performance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If semi-permeable membranes are used for Beta-Amyloid reduction, then Beta-Amyloid levels can be reduced, but the device complexity and maintenance burden increase significantly
Solution Approach 1:
The invention extracts the Beta-Amyloid binding function from the complex semi-permeable membrane system and concentrates it into a specific peptide sequence (KLVFF) that can be incorporated into the dialysate. This separation allows the membrane to perform only its basic filtration function while the peptide handles the specific Beta-Amyloid capture, significantly reducing device complexity and maintenance requirements.
Solution Approach 2:
The KLVFF peptide acts as an intermediary substance in the dialysate that mediates the interaction between the blood and the dialysis system for Beta-Amyloid removal. Instead of relying on the membrane's physical properties alone, the peptide provides a chemical binding mechanism that is easier to control and maintain.
2Reliability
If semi-permeable membranes are used for Beta-Amyloid filtration, then Beta-Amyloid levels can be reduced, but there is a risk that toxins may escape back into the body
Solution Approach 1:
The KLVFF peptide in the dialysate performs preliminary binding action on Beta-Amyloids before they can potentially escape back into the body. By having the binding agent present in the dialysate from the start, the system ensures that any Beta-Amyloids that pass through the membrane are immediately captured, preventing their return to the bloodstream.
Solution Approach 2:
The peptide serves as a protective intermediary that binds to Beta-Amyloids on the dialysate side of the membrane, creating an additional safety barrier that prevents toxin escape even if the membrane has imperfections or allows passage of certain molecules.
3Reliability
If standard dialysis machines are modified to incorporate Beta-Amyloid binding agents, then treatment effectiveness improves, but manufacturing cost increases
Solution Approach 1:
The invention makes the dialysate multi-functional by incorporating the KLVFF peptide binding agent into the standard dialysis solution. This allows the same dialysis machine to perform both standard dialysis functions and Beta-Amyloid specific removal without requiring specialized equipment modifications, thereby maintaining ease of manufacture while improving treatment effectiveness.
Solution Approach 2:
Instead of modifying the expensive and complex dialysis machine hardware, the invention copies the Beta-Amyloid binding function into the consumable dialysate solution. This approach transfers the functional enhancement to a replaceable component that can be manufactured more simply and replaced between treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces Beta-Amyloid levels in the subject by targeting and binding neurotoxic peptides specifically, avoiding the complexities of membrane evaluation and minimizing health risks, with a compact and inexpensive process.
Implementation Method 1
a capturing and binding agent for capturing and binding targeted Beta-Amyloids
Implementation Method 2
Beta-Amyloid peptide refers to a 39-43 amino acid peptide derived from the amyloid precursor protein (APP) by proteolytic processing... Beta-Amyloid 1-40 and Beta-Amyloid 1-42 aggregate into insoluble beta-sheet structures
Implementation Method 3
removing blood out of a body, passing the blood that is removed through a hollow fiber membrane
Implementation Method 4
a blood filtration device having a dialysate side and a blood circuit side... a permeable membrane that separates the blood circuit side and the dialysate side
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention provides a safe, reliable, and economical process for preparing an improved dialysis fluid formulation effective for extracorporeal treatment, through a blood filtration process, of a Beta-Amyloid associated pathological condition in a subject, said process comprises preparing a composition comprising KLVFF peptide, or a variant thereof, as the capturing and binding agent, and a carrier therefor, and mixing said composition with a dialysate solution. The process utilizes a compact, inexpensive, and simple standard dialysis machine that extracorporeally removes Beta-Amyloids without allowing escape of the Beta-Amyloids back into a subject's body, without having to intricately evaluate the performance and characteristics of a dialysis membrane, and without putting the health condition of the subject at risk.